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Open access under the ElSuramin is a polysulphonated naphthylurea with inhibitory activity against the human secreted group IIA
phospholipase A2 (hsPLA2GIIA), and we have investigated suramin binding to recombinant hsPLA2GIIA
using site-directed mutagenesis and molecular dynamics (MD) simulations. The changes in suramin
binding afﬁnity of 13 cationic residue mutants of the hsPLA2GIIA was strongly correlated with alterations
in the inhibition of membrane damaging activity of the protein. Suramin binding to hsPLA2GIIA was also
studied by MD simulations, which demonstrated that altered intermolecular potential energy of the sur-
amin/mutant complexes was a reliable indicator of afﬁnity change. Although residues in the C-terminal
region play a major role in the stabilization of the hsPLA2GIIA/suramin complex, attractive and repulsive
hydrophobic and electrostatic interactions with residues throughout the protein together with the adop-
tion of a bent suramin conformation, all contribute to the stability of the complex. Analysis of the hsPLA2-
GIIA/suramin interactions allows the prediction of the properties of suramin analogues with improved
binding and higher afﬁnities which may be candidates for novel phospholipase A2 inhibitors.
 2012 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Phospholipases A2 (PLA2 – EC 3.1.1.4)1 catalyze the hydrolysis of
the sn-2 acyl bonds of sn-3 phospholipids [1], and are classiﬁed in 16
groups according to amino acid sequence similarity [2]. The human
secreted group IIA PLA2 (hsPLA2GIIA) is found in high concentrations
in inﬂammatory ﬂuids [3] and tears [4], and shows elevated levels of
expression in intestinal Paneth cells [5] and macrophages [3,6]. Fur-
thermore, hsPLA2GIIA expression is induced by endotoxins and cyto-
kines, and is generally regarded as a pro-inﬂammatory protein [7].
The hsPLA2GIIA shows a potent anti-microbial activity against
Gram-positive bacteria, in which catalytic [8] and non-catalytic [9]
mechanisms contribute to permeabilization of the plasma mem-
brane and cell death. The high number of cationic amino acid resi-
dues lends the hsPLA2GIIA a strongly basic character (pI = 10.5),
and consequently the protein shows hydrolytic activityde Química, Faculdade de
idade de São Paulo, Avenida
ibeirão Preto, SP, Brazil. Fax:
lrp.usp.br (R.J. Ward).
2GIIA, the secreted group IIA
sevier OA license.preferentially against membranes comprised of anionic phospholip-
ids, such as liposome membranes containing lipids with phosphot-
idylglycerol head-groups and the plasma membrane of Gram-
positive bacteria [10,11].
Various compounds reduce the inﬂammatory effects of PLA2s by
acting as competitive inhibitors [12–15], including indoles [16],
oxoamides [17], vitamin E [18] and ﬂavonoids [19]. It has recently
been demonstrated that the polysulfonated naphthylurea suramin
binds to the hsPLA2GIIA, resulting in the inhibition of catalytic
activity and macrophage activation yet without inhibiting the bac-
tericidal effect of the protein [20]. Furthermore, molecular dynam-
ics (MD) simulations of the hsPLA2GIIA/suramin complex together
with isothermal titration calorimetry experiments suggested sura-
min binding is mediated by three regions located on the phospho-
lipid membrane recognition surface of the protein [21]. The
location of the suramin binding sites is consistent with the ob-
served inhibition of the phospholipase activity, and represents a
novel type of PLA2/inhibitor interaction. The characterization of
new PLA2 inhibitors leads the development of therapeutic strate-
gies for treatment of pathological processes provoked by these en-
zymes, and we have therefore extended the mapping of suramin
binding sites of the hsPLA2GIIA by site-directed mutagenesis,
functional studies of the membrane damaging activity and MD
simulations.
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Site directed mutagenesis
The cloning of the full-length cDNA encoding the hsPLA2GIIA
(GenBank Accession BC 005919) into the expression vector pET3a
has been described previously [20]. Site directed mutagenesis of
the hsPLA2GIIA was performed as previously described using PCR
mutagenesis [9] to introduce a total of 13 single cationic charge
elimination mutations (oligonucleotides used are shown in Table
1). The ﬁnal PCR fragments were cloned into the expression vector
pET3a and fully sequenced. After expression as inclusion bodies in
Escherichia coli BL21, the proteins were refolding and puriﬁed as
previously described [20].
Suramin binding by intrinsic suramin ﬂuorescence emission
Wild-type hsPLA2GIIA or mutants at a concentration of 3 lM
were titrated with suramin (Sigma–Aldrich, St. Louis, MO, USA)
over the concentration range 0–100 lM in a buffer containing
20 mM NaH2PO4, 150 mM NaCl, pH 7.2. The changes in intrinsic
suramin ﬂuorescence emission were measured with a Spectronic
SLM 8100C spectroﬂuorimeter at 25 C, using a stirred 1 cm optical
path length quartz cuvette. The samples were excited at 350 nm
and the emission spectrum was measured between 375 and
500 nm. Suramin absorbance at 350 nm leads to an inner ﬁlter ef-
fect, therefore the ﬂuorescence emission intensities were corrected
using a molar extinction coefﬁcient of 7060 cm1 M1 as derived
from an appropriate suramin calibration curve. After normalization
of the ﬂuorescence emission signal, the equilibrium dissociation
constant (KD) for each suramin/protein complex was estimated
by nonlinear curve ﬁtting with a sigmoidal dose–response function
using the OriginPro 8 software (OriginLab Corporation, Northamp-
ton, MA, USA).
Effect of suramin on the Ca2+ independent membrane damaging
activity of the hsPLA2GIIA
The Ca2+-independent membrane damaging activity was evalu-
ated by the ﬂuorescence increase due to the release of the liposome
entrapped self-quenching ﬂuorescent dye calcein. Unilamellar lip-
osomes composed of dioleoyl phosphatidylcholine (DOPC – Sigma–
Aldrich, St. Louis, MO, USA) and dioleoyl phosphatidylglycerol
(DOPG – Sigma–Aldrich, St. Louis, MO, USA) at a 1:1 M ratio con-
taining 25 mM calcein (Sigma–Aldrich, St. Louis, MO, USA) in buf-
fer containing 20 mM Hepes, 20 mM NaCl were prepared byTable 1
Oligonucleotide sequences of primers used for the generation of the charge
elimination site-directed mutants of the hsPLA2GIIA.
R7A TGATCATTGCGTGGAAATT
K15A GCGGCTTCCGCTCCTGTCGT
K38A CCGTTGCATCCGCGGGGGATCC
H48Q AGCAACAGTCGTTAGTGACACA
D49K GTAGCAACATTTATGAGTGACACA
K53A CCAGACGTGCGTAGCAACA
R54A CTCCAGAGCTTTGTAGCA
K57A CCACGTGCCTCCAGACG
R58A GCCACATCCAGCTTTCTCCAG
DK57/R58 GGTGCCACATCCACGTTTCTCCAGACGTTTGTA
K115A GGTACTTTGCATTGTAGGT
K116A ACTGGTACGCTTTATTGTA
K123A CTGCAGTGTGCATTGGAATA
All sequences are shown in the 50–30 direction, and the underlined bases indicate
the codon that was introduced during the mutagenesis.reverse phase evaporation [22]. Suramin at a concentration of
0.75 lMwas pre-incubated for 15 min with 4 lg/mL of hsPLA2GIIA
or mutants, and added to the liposome to a ﬁnal protein:lipid mo-
lar ratio of 1:200. Membrane damage induced by the protein was
monitored by the increase in ﬂuorescence emission at 520 nmwith
excitation at 490 nm, and the signal was expressed as the percent-
age of total calcein liberation on addition of 5 mM Triton X-100.
The effect of suramin was measured in ﬁve independent experi-
ments, and the data were analyzed using ANOVA with a subse-
quent Tukey test.Molecular dynamics simulations of the hsPLA2GIIA/complex
All MD simulations were carried out using the GROMACS 4.5
software package [23] and the GROMOS-96 (43A2) force ﬁeld
[24] in constant volume (NVT ensemble) using the ‘‘leapfrog’’ algo-
rithm [25] with a time step of 2.0 fs. The systems for MD simula-
tions were constituted by 16,500 SPC water molecules [26], a
monomer of hsPLA2GIIA (PDB code 1POE, [27]) and a single sura-
min molecule. A cubic simulation box was adjusted to give a den-
sity of 0.997 kg L3 for the water molecules. The initial suramin
localization on the surface of the hsPLA2GIIA was made by a
20 ns extension of the previously described simulation of the
hsPLA2GIIA/complex using the same parameters [21]. The mutants
R7A, R58A, K116A and DK57/R58 (a mutant in which residues K57
and R58 are deleted) were also investigated by MD simulations.
The initial conﬁgurations for these mutants were based on the sim-
ulated structure of wild-type hsPLA2GIIA/suramin complex [21], in
which the particular mutation under study had been introduced.
All the simulations were run with the total time of 20 ns and the
atomic trajectories were sampled each 40 ps. The long-range inter-
actions were treated using the particle-mesh Ewald sum (PME)
method [28] and calculated with a cutoff of 1.4 nm, and the inter-
molecular Interaction Potentials (IIP) were computed within the
same cutoff distance. Electrostatic potential surfaces around
wild-type hsPLA2GIIA and mutants/suramin complexes were cal-
culated with the Poisson–Boltzmann equation with APBS [29]
and PDB2PQR [30].Results and discussion
Scanning alanine mutagenesis of 13 cationic residues has been
used to evaluate the mapping of the suramin binding sites on the
hsPLA2GIIA. Dideoxynucleotide sequencing of all 13 mutants con-
ﬁrmed that the only differences observed between the wild-type
and mutant hsPLA2GIIA coding sequences were those introduced
during the mutagenesis procedure. The far ultraviolet circular
dichroism spectra of all mutants (Supplementary Fig. S1) present
a spectral proﬁle that is similar to the wild-type hsPLA2GIIA with
minima at 209 and 222 nm, which are typical of proteins that are
rich in a-helical structure, and are similar to those previously re-
ported for the recombinant hsPLA2GIIA [9,20]. The results demon-
strate that the refolding and puriﬁcation procedures yielded wild-
type and mutant proteins with native-like secondary structure.
The polysulphonated naphthylurea suramin has a long history
of use as an antiprotozoal and anthelminitic drug [31,32], and
more recently has attracted interest due to its antineoplastic and
antiangiogenic activities (see the discussion in [20] for a brief re-
view of the recent literature). As a polyanion, suramin forms stable
interactions with cationic surfaces of basic proteins [33,34], and in
the present study suramin binding to the hsPLA2GIIA and mutants
was evaluated by changes in the intrinsic suramin ﬂuorescence
intensity. Fig. 1 shows that on suramin binding, the suramin intrin-
sic ﬂuorescence emission at 440 nm increases in a sigmoid manner
for all proteins. The equilibrium dissociation constant (KD) for all
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shown in Supplementary Table S1. The wild-type hsPLA2GIIA
presents a KD of 6.3 lM, and the suramin afﬁnity of the hsPLA2GIIA
was signiﬁcantly reduced by the mutations K15A (located in the N-
terminal, KD = 28.4 lM), R54A (close to the active site,
KD = 12.5 lM) and K123A (in the C-terminal loop region,
KD = 9.7 lM). These results suggest that these three regions of
the protein contribute to binding the suramin. In contrast, the mu-
tants D49K (active site, KD = 3.3 lM), DK57/R58 (hydrophobic sub-
strate binding channel, KD = 2.1 lM) and K116A (C-terminal loop,
KD = 3.8 lM) increased the suramin afﬁnity relative to the wild-
type protein.
We have recently demonstrated that in addition to its Ca2+-
dependent hydrolytic activity, the hsPLA2GIIA also displays a
Ca2+-independent membrane damaging activity [9]. The Ca2+-inde-
pendent membrane permeabilizing activity was evaluated by mea-
suring the calcein release from liposomes comprised of mixed
DOPC/DOPG phospholipids, which is a lipid mixture that has been
previously used to study the mechanism of action of the hsPLA2-
GIIA [9,35]. Fig. 2A presents the percentage of calcein release by
wild-type and mutant hsPLA2GIIA both in the absence of suramin
and after incubation with suramin at a concentration of 0.75 lM. In
the absence of suramin, no signiﬁcant differences in the Ca2+-inde-
pendent membrane permeabilizing activity were observed be-
tween the wild-type and the mutant proteins (Fig. 2A – light
grey bars). Under the chosen conditions suramin inhibits approxi-
mately 50% of the calcein release caused by the wild-type hsPLA2-
GIIA, and reduces the Ca2+-independent membrane permeabilizing
activity of all mutants (Fig. 2A – dark grey bars). The inhibition of
the membrane damaging effect by suramin was quantiﬁed as the
percentage reduction in the calcein release in the presence of sur-
amin as compared to the effect in the absence of suramin (see
Fig. 2B). The inhibitory effect of suramin in relation to wild-type
protein was reduced in the R7A, K15A, R54A, R58A and K123A mu-
tants, and enhanced in the H48Q, D49K and K116A mutants.
Comparison of the results of the liposome membrane damaging
activity assays with those from the suramin binding experiment
shows a strong correlation. The mutants K15A, R54A and K123A,
which have reduced suramin afﬁnities, also present a reducedFig. 1. Suramin ﬂuorescence intensity changes on interaction with the wild-type
hsPLAGIIA and mutant proteins. Suramin binding to the hsPLAGIIA and mutants
was evaluated by the increase in intrinsic suramin ﬂuorescence emission at 440 nm.
The curves show ﬂuorescence changes on titration of the wild type hsPLAGIIA (solid
squares) and mutants R7A (open circles), K15A (open up triangles), K38A (solid
down triangles), H48Q (solid diamonds), D49K(solid up triangles), K53A (crosses),
R54A (open hexagons), K57A (open right triangles), R58A (open left triangles),
DK57/R58 (solid circles), K115A (solid hexagons), K116A (solid stars) and K123A
(open diamonds). See materials and methods for further experimental details.inhibition of the calcein release from liposomes. In contrast, the
mutants H48Q and D49K (located in the active site region of the
protein) and K116A (located in the C-terminal region), all of which
present an increased afﬁnity for suramin, were inhibited to a great-
er degree in relation to the wild-type protein. Finally, the mutants
R7A, R58A and DK57/R58 showed no correlation between afﬁnity
and suramin inhibition. To gain further insights as to underlying
structural basis of these results, molecular dynamics simulations
were performed on hsPLA2GIIA/suramin and R58A, DK57/R58
and K116A mutant/suramin complexes.Molecular dynamics (MD) simulations
Based on the electrostatic properties of both the hsPLA2GIIA
and suramin, three possible suramin binding regions on the mem-
brane recognition surface of the protein have been previously been
proposed [21]. Analysis of the hsPLA2GIIA/suramin complex in MD
simulations suggested two alternative conformations of the bound
suramin involving three regions on the protein; (1) the substrate
binding/active-site region, (2) residues in the N-terminal region,
and (3) residues in the C-terminal region of the protein [21].
Although these previous results corroborate the experimental data
obtained in the present work, the unexpected properties of some
mutants prompted us to investigate the suramin binding to the
hsPLA2GIIA in more detail by MD simulations of suramin com-
plexes with mutants that either maintained (R58A) or increased
(DK57/R58, K116A) the afﬁnity as measured by the changes in
intrinsic suramin ﬂuorescence.
MD simulations provide a trajectory of atomic positions, and
calculation of the Intermolecular Interaction Potential (IIP) be-
tween the hsPLA2GIIA and the suramin allows the direct evalua-
tion of the stability of the hsPLA2GIIA/suramin complex in
aqueous solution. Reliable IIP calculations depend on an ensemble
of hsPLA2GIIA and suramin structures generated by MD that are at
equilibrium, which is properly evaluated by calculation of the root
mean square deviations (RMSD) from the initial structure for all
protein Ca atoms. The IIP and RMSD averages were computed over
the 20 ns trajectories, and the average RMSD(t) values for the pro-
tein Ca atoms in the simulated complexes are 0.24 ± 0.02 nm
(hsPLA2gIIA), 0.23 ± 0.03 nm (R58A), 0.17 ± 0.02 nm (DK57/R58)
and 0.22 ± 0.04 nm (K116A). These results indicate that the
hsPLA2GIIA structures are not signiﬁcantly altered either as a con-
sequence of the mutations or as a result of suramin binding.
The IIP per residue in the protein/suramin complexes can pro-
vide further insights as to the contributions of individual residues
to the interaction potential. Fig. 3 shows IIP per residue for the
hsPLA2GIIA and mutant proteins, where residues which present a
negative IIP are those with attractive interactions with the suramin
molecule, and those residues that have positive potentials contrib-
ute to repulsive interactions. For example, residue R54 is located
close to the C-terminal region of the protein and due to the prox-
imity of the suramin sulphonate groups presents an average inter-
molecular potential energy value of -74.8 kJ mol1. The value of the
potential varies over the range of 69.00 to 80.00 kJ mol1, and
this residue can therefore be considered to make a signiﬁcant con-
tribution to suramin binding, and readily explains the observed
reduction in the hsPLA2gIIA/suramin afﬁnity of the K54A mutant.
Table 2 presents the IIP for selected residues that present highly
attractive interactions in different mutants, and which can be con-
sidered as component of suramin binding sites. Residues R7, K10
and K15 are located in the N-terminal region and K115, K116
and K123 in the C-terminal region, and all residues show different
IIP values between the different mutants. This demonstrates that
the contribution of a given residue to the formation of different
mutant/suramin complexes is not necessarily constant, and is
Fig. 2. (A) The effect of suramin on the membrane-damaging activity of the wild-type hsPLA2GIIA and mutants as measured by the release of the encapsulated ﬂuorescent
marker calcein from DOPC:DOPG liposomes. (B) Percentage inhibition by suramin of the membrane-damaging activity of the hsPLA2GIIA and mutants. Calcein liberation is
expressed as the percentage of total marker release after addition of 5 mM Triton X-100. Results are presented as the mean ± SD (n = 3). The mutants R7A, K15A, R54A, R58A
and K123A signiﬁcantly reduced the activity (p < 0.05) in relation to the wild-type protein.
Fig. 3. Intermolecular Interaction potential per residue of suramin/hsPLA2GIIA and
suramin/mutant complexes calculated from 20 ns MD trajectories. The arrows
indicate positions 7 (left), 57 and 58 (middle), 115 and 116 (right).
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surface potential.Table 2
Intermolecular interaction potential (IIP) for residues in the N- and C-terminal sites. The val
K113, K114 and K121 due to deletion of two residues.
RESIDUE hsPLA2GIIA K116A
R7 69.5 ± 18.9 71.8 ± 7.0
K10 71.6 ± 21.0 69.5 ± 10.0
K15 58.2 ± 15.0 67.9 ± 8.1
K115 81.5 ± 21.8 87.2 ± 29.2
K116 79.4 ± 29.3 3.81 ± 0.96
K123 177.2 ± 59.7 243.4 ± 40.1The IIP between suramin and the hsPLA2GIIA or mutants is
619 ± 90 kJ mol1, which compares with values of 642 ±
92 kJ mol1 (R58A/suramin), 837 ± 80 kJ mol1 (DK57/R58/
suramin) and 865 ± 79 kJ mol1 (K116A/suramin), demonstrat-
ing that the elimination of cationic residues at these different posi-
tions resulted in a more attractive interaction between the
hsPLA2GIIA and suramin. The lowest IIP were calculated for the
DK57/R58 and K116A and would predict a higher suramin afﬁnity
for these mutants, which indeed is corroborated by the experimen-
tal measurements.
The electrostatic potential at the molecular surfaces of the com-
plexes between suramin and the wild-type hsPLA2GIIA and mu-
tants are shown in Fig. 4. The potential at the surface of the
protein varies between the mutants, and consequently the bound
suramin molecule undergoes conformational changes in order to
optimize the docking of the sulphonate groups to the protein sur-
face. In all mutants, the more hydrophobic central region of the
suramin molecule ﬁts within the hydrophobic substrate-binding/
active-site of the protein, a situation that is not observed in wild-
type hsPLA2GIIA. Furthermore, the suramin adopts a bent confor-
mation with one of its ends oriented directly towards the C-termi-
nal loop, while the other end is closer to the region of the catalytic
site and residues 57 and 58 on one of the long a-helices. The con-
formations of the bound suramin that are observed in the present
study were not detected in previous investigations [21], which
suggest that the altered surface potential resulting from mutations
in the hsPLA2GIIA can lead to variation in the optimal conforma-
tion of the bound suramin.
The IIP results presented in Fig. 3 and in Table 2 together with
the electrostatic potential molecular surfaces presented in Fig. 4
provide a virtual contact map of the attractive and repulsiveues are given in kJ/mol. In case of DK57/R58, the residues K115, K116 and K123 are the
R58A R7A DK57/R58
73.4 ± 5.4 1.73 ± 0.43 54.9 ± 15.0
79.3 ± 5.7 84.2 ± 7.42 66.9 ± 15.0
77.4 ± 14.7 80.6 ± 10.4 72.2 ± 17.2
147.6 ± 43.1 83.3 ± 13.6 86.4 ± 26.2
184.6 ± 59.1 149.3 ± 42.2 139.5 ± 51.3
214.4 ± 28.3 220.2 ± 28.2 230.5 ± 56.1
Fig. 4. Electrostatic potential molecular surfaces of representative structures
obtained from MD trajectories of suramin complexes with the wild-type
hsPLA2GIIA and the mutants R58A, K116A and D57/58. The localization of residues
R7 and K10 (labeled A) and K15 (labeled B) contribute to the main interaction sites
on the N-terminal, and the residues of the main interaction sites on C-terminal are
K115 and K116 (labeled C) and K123 (labeled D). The localizations of the residues
with high repulsive intermolecular potential energy are shown in red and blue for
the closest to, and more distant from, the suramin molecule. Contour levels are in
dimensionless units of 10kT/e (red) to 10kBT/e (blue), where k is the Boltzmann’s
constant, T is the temperature in Kelvin and e is the elementary charge. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred
to the web version of this article.)
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the changes in the afﬁnity can be predicted. The data in Table 2
show that the IIP between the selected residues and the suramin
changes depending on the mutation in the hsPLA2GIIA. Residues
in the N-terminal region (R7, K10 and K15) show little variation
in the IIP, indicating that these positions are insensitive to the ef-
fects of the mutations. In contrast, residues in the C-terminal loop
(K115, K116 and K123) showed a signiﬁcant reduction in the IIP.
The K115 residue is only sensitive to the R58A mutation, which re-
sulted in an increased in the attractive interaction with the sura-
min. In the case of the K116 residue, more attractive interactions
with suramin were observed in the R58A, R7A and DK57/R58 mu-
tants. Finally, the K123 residue shows an enhanced IIP with sura-
min in all mutants, especially in the case of the K116A mutation.
This shows that within the C-terminal region, the attractive inter-
action of the K123 residue with the suramin is particularly inﬂu-
enced by the K116 residue, and this the difference in the suramin
conformation in the K116A mutant, whose position is closer to
the K123 residue than the other mutants (Fig. 4).
The main sources of repulsion in the hsPLA2GIIA/suramin com-
plexes (shown as positive potentials in Fig. 3) include the nega-
tively charged residues E16, G38, D41, D48, E55, D81, E89 and
D91, which present variations in intermolecular potential energy
from +80 to +100 kJ mol1. These residues can be divided into
two groups, the ﬁrst (A and B in Fig. 4) are located in the a-helix
more distant from suramin molecule and the second (C and D)
are located closer to the suramin molecule. This information could
be useful for the design of new hsPLA2GIIA inhibitors based on the
chemical structure of suramin, where we suggest the maintenance
of a high density of negative charges at the extremities but a re-
duced negative charge in the central region of the molecule. Fur-
thermore, shortening of the central region of the suraminmolecule by removing one or two rings could facilitate a bent con-
formation of the bound molecule that optimizes contact with C-
terminal region of the hsPLA2GIIA.
In conclusion, site-directed mutagenesis of the cationic residues
of the hsPLA2GIIA had variable effects on the afﬁnity of suramin for
the protein. In those mutants that showed increased suramin afﬁn-
ity, a signiﬁcant conformational change of the suramin molecule
was observed as a result of the modiﬁed potential surface of the
protein induced by mutations, which was unrelated to any of the
suramin conformations previously observed in the hsPLA2GIIA/
suramin complex. In the case of K116A and DK57/R58 mutants,
the suramin molecule presented a bent conformation favoring
interactions with residues in the C-terminal region. We conclude
that the C-terminal region is crucial to the stabilization of the
hsPLA2GIIA/suramin complex and consequently is a major struc-
tural determinant of the inhibitory action of suramin. We suggest
that mutations which modify the potential surface of the protein
may also promote a bent suramin conformation, which increases
the complex stability. In addition to contributing to the under-
standing of hsPLA2GIIA/inhibitor interactions, the present study
has demonstrated the viability of using MD simulations not only
for the interpretation of experimental results, but also for the de-
sign of new compounds for hsPLA2GIIA inhibitors that are based
on the suramin molecule.
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